Development Pipeline

Five-phase clinical development program targeting systemic age reversal through the Bio-Energetic Sequencing Model.

P1

NAD+ Restoration Protocol

Optimized NMN/NR delivery systems with enhanced bioavailability. Sirtuin activation cascade monitoring through validated biomarkers.

NMN NR SIRT1/3/6 CD38 Inhibition
Active

Clinical validation Q2 2026

P2

Autophagy Activation System

AMPK activation and mTOR modulation protocols. Spermidine-enhanced cellular cleanup with autophagosome flux monitoring.

Spermidine AMPK mTOR Inhibition Fasting Mimetics
Development

IND filing Q4 2026

P3

Senolytic Clearance Protocol

Targeted senescent cell elimination using optimized D+Q and Fisetin combinations. SASP reduction monitoring.

Dasatinib Quercetin Fisetin SASP Markers
Development

Phase I trial 2027

P4

Regenerative Medicine Platform

Stem cell niche optimization with BPC-157, exosome therapy, and growth factor modulation for tissue regeneration.

BPC-157 Exosomes MSC Activation GH Secretagogues
Research

Preclinical 2027-2028

P5

Epigenetic Optimization

Methylation pattern restoration via partial Yamanaka factor induction. Epigenetic clock reversal with rapamycin protocols.

Rapamycin Yamanaka Factors DNA Methylation GrimAge
Planned

Research phase 2028+

5

Development Phases

74

Scientific Citations

$8M

Clinical Development Budget

2026-28

Development Timeline

Partner With Us

Join our $20M Series A to accelerate the development of systemic age reversal protocols.

View Investment Opportunity